

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999      • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com)      • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

26<sup>th</sup> December, 2025

To,

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	---

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”).**

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, this is to inform you that the Company has acquired 64,02,018 equity shares at issue price of Rs. 468.60 per equity share aggregating to Rs. 299,99,85,634.80/- ('Rights Shares') offered by Enzene Biosciences Limited (“Enzene”), a subsidiary of the Company, on a rights basis. The Company has been allotted aforesaid Rights Shares by Enzene on 26<sup>th</sup> December, 2025.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Master circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as Annexure I. A copy of this disclosure will be made available on the Company's website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,  
For **Alkem Laboratories Limited**

**Manish Narang**  
**President – Legal, Company Secretary & Compliance Officer**

Encl: a/a

**Annexure I**

Particulars	Remarks
Name of the target entity, details in brief such as size, turnover etc.:	Enzene Biosciences Limited, a subsidiary of the Company ("Enzene") in India having a turnover of INR 363.62 crores for the financial year ended 31 <sup>st</sup> March, 2025.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms-length"	Acquisition does not fall within the purview of related party transaction.
Industry to which the entity being acquired belongs	Biosimilars and biologics contract manufacturing.
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To meet capital expenditure (capex) and working capital requirements.
Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
Indicative time period for completion of the acquisition	Equity shares were allotted on 26 <sup>th</sup> December, 2025.
Consideration- whether cash consideration or share swap and details of the same	Cash consideration.
Cost of acquisition or the price at which the shares are acquired;	Rs. 299,99,85,634.80/-. 64,02,018 equity shares at issue price of Rs. 468.60 per equity share.
Percentage of shareholding / control acquired and/or number of shares acquired;	The shareholding of the Company in Enzene is 99.61% of equity share capital of Enzene post allotment of 64,02,018 equity shares at issue price of Rs. 468.60 per equity share on rights basis.



## ALKEM LABORATORIES LTD.

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com) • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

Enzene was incorporated on 28<sup>th</sup> August, 2006 under the provisions of the Companies Act, 1956. It is engaged in the business of (i) research & development, manufacturing and out licensing of biosimilar products; and (ii) contract development and/or contract manufacturing for biosimilars, novel biologics, within India and/or outside India.

**Turnover details:**

FY 2024-2025: INR 363.62 crores

FY 2023-2024: INR 262.66 crores

FY 2022-2023: INR 144.00 crores